{
    "root": "23bbd301-54b0-447b-93c1-a6ff1e13ce4f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ARBLI",
    "value": "20250320",
    "ingredients": [
        {
            "name": "LOSARTAN POTASSIUM",
            "code": "3ST302B24A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6541"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11074"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC",
            "code": "GR686LBA74",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC",
            "code": "3980JIH2SW",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        }
    ],
    "indications": {
        "text": "arbli angiotensin ii receptor blocker ( arb ) indicated : treatment hypertension , lower blood pressure adults children greater 6 years old . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions . ( 1.1 ) reduction risk stroke patients hypertension left ventricular hypertrophy . evidence benefit apply black patients . ( 1.2 ) treatment diabetic nephropathy elevated serum creatinine proteinuria patients type 2 diabetes history hypertension . ( 1.3 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "nephropathy (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "proteinuria (DOID:576)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_576"
            },
            {
                "text": "type 2 diabetes (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "hypertension usual adult dose : 50 mg orally daily . ( 2.2 ) usual pediatric starting dose : 0.7 mg per kg orally daily ( 50 mg ) . ( 2.2 ) hypertensive patients left ventricular hypertrophy usual starting dose : 50 mg orally daily . ( 2.3 ) add hydrochlorothiazide 12.5 mg and/or increase arbli 100 mg orally followed increase hydrochlorothiazide 25 mg blood pressure response needed . ( 2.3 , 14.2 ) nephropathy type 2 diabetic patients usual dose : 50 mg orally daily . ( 2.4 ) increase dose 100 mg orally daily blood pressure response needed . ( 2.4 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "nephropathy (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "arbli ( losartan potassium ) white , translucent oral suspension . ml contains 10 mg losartan potassium ( equivalent 9.2 mg losartan ) . supplied 165 ml high-density polyethylene ( hdpe ) bottle child-resistant cap tamper-evident seal . shake 20 seconds prior . ndc 83245-053-06 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep container tightly closed . protect light . store dispense original container . bottle opened , within 60 days .",
    "adverseReactions": "arbli contraindicated : patients hypersensitive component product . co-administration aliskiren patients diabetes .",
    "indications_original": "Arbli\u00a0is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 )",
    "contraindications_original": "Hypertension Usual adult dose: 50 mg orally once daily. ( 2.2 ) Usual pediatric starting dose: 0.7 mg per kg orally once daily (up to 50 mg). ( 2.2 ) Hypertensive Patients with Left Ventricular Hypertrophy Usual starting dose: 50 mg orally once daily. ( 2.3 ) Add hydrochlorothiazide 12.5 mg and/or increase Arbli to 100 mg orally followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. ( 2.3 , 14.2 ) Nephropathy in Type 2 Diabetic Patients Usual dose: 50 mg orally once daily. ( 2.4 ) Increase dose to 100 mg orally once daily if further blood pressure response is needed. ( 2.4 )",
    "warningsAndPrecautions_original": "Arbli (losartan potassium)is a white, translucent oral suspension. Each mL contains 10 mg losartan potassium (equivalent to 9.2 mg losartan). \u00a0It is supplied as 165 mL in a high-density polyethylene (HDPE) bottle with a child-resistant cap and tamper-evident seal. Shake for 20 seconds prior to each use. \n                  NDC 83245-053-06\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.\n                  Store and dispense in original container. Once the bottle is opened, use it within 60 days.",
    "adverseReactions_original": "Arbli\u00a0is contraindicated:\n                  \n                     In patients who are hypersensitive to any component of this product.\n                     For co-administration with aliskiren in patients with diabetes.",
    "drug": [
        {
            "name": "ARBLI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6541"
        }
    ]
}